Cancer therapy: can the challenge be MET?

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Deregulation of tyrosine kinase receptors (RTKs) is common in human cancers, correlating with aggressive tumor phenotypes.
• The Met oncogene, encoding a key RTK for hepatocyte growth factor (HGF), regulates cell growth, invasion, and apoptosis.
• Met activation is critical for tumor development and achieving an invasive, metastatic phenotype.

Purpose of the Study:

• To investigate the role of Met receptor tyrosine kinase (RTK) deregulation in human tumorigenesis and metastasis.
• To explore the mechanisms by which Met contributes to cancer progression.
• To evaluate the potential of targeting Met activation as a therapeutic strategy against cancer.

Main Methods:

• Analysis of Met oncogene deregulation in human tumors.
• Investigation of Met signaling pathways controlling cell growth, invasion, and apoptosis.
• Examination of Met interactions with other membrane receptors (e.g., integrins, plexins, CD44, FAS).

Main Results:

• Met deregulation is frequently observed in human tumors and linked to aggressive phenotypes.
• Activated Met signaling drives tumorigenic properties and facilitates invasive behavior.
• Met interacts with various unrelated membrane receptors, contributing to its oncogenic functions.

Conclusions:

• Met receptor tyrosine kinase (RTK) plays a pivotal role in human cancer development and progression.
• Targeting Met activation presents a novel and challenging therapeutic avenue to inhibit tumor growth and metastasis.